COMMITTED TO INNOVATION AND SOLIDARITY

initiative  OCTALFA’s mission is two fold : to facilitate innovation and provide support to vulnerable people.

Initiative  OCTALFA works to bring about innovation in healthcare by incubating innovative startups in France..

Initiative  OCTALFA also supports projects aimed at improving quality of life for cancer patients and disabled people in France and Madagascar.

OUR ORGANISATIONS

OCTALFA creates, funds and manages young innovative companies
OTONNALE incubates innovative projects until they mature into fledgling companies
The corporate foundation Fondation Dominique & Tom Alberici – OCTALFA supports charity and non-profit projects addressing the challenges surrounding cancer and disabilities in France and Madagascar
The endowment fund Institut Dominique & Tom Alberici raises additional funds for projects supported by our corporate foundation

 OUR TEAM

  • Gilles Alberici
    Chairman

    Gilles has 30 years of experience in the pharmaceutical and biotechnology sectors. He created and developedOPi, Pharmaceuticals for Rare Diseases and has taken more than ten products through clinical trials.

  • Julien Alberici
    Managing Director

    Julien is a graduate of EMLYON Business School and iaelyon management school. He has worked as a consultant in innovation management, business development andfinancial analysis,and is currently the Chief Executive Officer and co-founder ofMathym.

  • Jeremy Bastid
    R&D Director

    Jeremy is a pharmacist and oncologist, who specialises in immuno-oncology. He joined initiative OCTALFA in 2010 and manages OREGA Biotech as Chief Operating Officer.

  • Charlotte Maddalena
    Executive Assistant

    Charlotte Maddalena joined initiative OCTALFA in October 2016 as an executive assistant. Charlotte is also responsible for the administrative management of the Foundation’s projects.

 OUR  HISTORY

Formed in 2006, OCTALFA is the fruit of previous work carried out by Gilles Alberici, in particular during his time at OPi, a company that develops drugs for orphan diseases.

OCTALFA began by helping established innovative companies with financing operations. It founded and/or invested in 14 companies in France.Since 2016, OCTALFAconcentrates its efforts to the development and management of its subsidiaries.

OTONNALEincubates innovative industrial or academic projects selected by initiative  OCTALFA until they reach maturity.

Spearheaded by Dominique Alberici, OCTALFA created the OCTALFA Corporate Foundation in 2008 to provide help for cancer patients and disabled people. The corporate foundation was named Fondation Dominique & Tom Alberici – OCTALFA in 2011, following the passing away of Tom, Dominique and Gilles’ son.

Founded in 2012, the endowment fund Institut Dominique & Tom Alberici complements the corporate foundation’s activities by supporting charity projects that require both a more hands-on approach and additional funding. This funding is provided by OCTALFA and our donors.

► NEWS

  • Three projects supported by our Foundation

    On 3rd of february 2017, the Board of Directors of the Foundation decided to support Association Française du Syndrome de Rett (respit stay at Center Parc), Audition Solidarité (recycling hearing aids) and SLA Aide et Soutien (buy three computers)

  • Merry Christmas and Happy New year 2017 !

    initiative OCTALFA wishes you a Merry Christmas and a Happy New Year 2017 !

  • December 2016 newsletter

    Read the newsletter of the endowment fund Institut Dominique et Tom Alberici

  • Alize Pharma to attend J.P. Morgan

    J.P. Morgan 35th Annual Healthcare Conference 2017 will take place 9 – 13 January 2017 in San Francisco, CA, USA1

  • Two projects supported by our Endowment Fund

    On 17th of November 2016, the Foundation decided to support, throught its endowment fund Institut Dominique et Tom Alberici, SOHDEV and Traces de Vie.

  • One project supported by our Foundation

    On 17th of November 2016, the Board of Directors of the Foundation decided to support SOHDEV.

  • Mathym closes its second financing round

    The proceeds will be used to implement the first manufacturing line and conduct the R&D programs

  • Antagene joints Cerba Healthcare

    ANTAGENE joins CERBA VET to form a European veterinary diagnostic leader